|
 |
| LETTER TO THE EDITOR |
|
|
|
| Year : 2014 | Volume
: 46
| Issue : 4 | Page : 460 |
| |
Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients
Sanjay Hadigal, K Ashok Shenoy
Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India
| Date of Web Publication | 4-Jul-2014 |
Correspondence Address:
Sanjay Hadigal
Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.135970
How to cite this article:
Hadigal S, Shenoy K A. Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol 2014;46:460 |
How to cite this URL:
Hadigal S, Shenoy K A. Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol [serial online] 2014 [cited 2023 Apr 1];46:460. Available from: https://www.ijp-online.com/text.asp?2014/46/4/460/135970 |
Sir,
I read with interest the above mentioned article. [1] However, I had a few comments to make regarding the same. The method used to arrive at the particular sample size was not mentioned and neither was the power of the study. Some of the data mentioned in the written content did not correlate with the data that was mentioned in the graph. The authors mentioned that atorvastatin reduced LDL-C the most at a dose of 40 mg (15.9%). However, [Table 3] clearly mentions that atorvastatin at a dose of 20 mg reduced LDL-C the most (21.2%). In [Figure 1]b, the footnote of the graph wrongly mentions microalbuminia instead of microalbuminuria.
As the authors had used the term cost-effectiveness in the study title, it would have been better if they had shed more light on the pharmacoeconomic analysis. They have solely mentioned the acquisition cost of rosuvastatin when compared to atorvastatin. A cost-effective analysis with the calculation of the Incremental Cost Effectiveness Ratio would have been more appropriate and insightful.[2]
| » References | |  |
| 1. | Bener A, Dogan M, barakat L, Al-Hamaq AO. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol 2014;46:88-93. 
[PUBMED]  |
| 2. | Lisa AS. Pharmacoeconomics: Principles, Methods and Applications In: Joseph TD, Robert LT, Gary CY, Barbara GW, Michael L, editors. Pharmacotherapy: A Pathophysiological Approach. 7 th ed. New Delhi: McGraw-Hill; 2008. p. 1-14.
|
|
